FIG 1.

Mean SCr and UrNGAL levels during 2 weeks of treatment with intravenous AmB. (a) SCr and UrNGAL levels stratified by AKI according to the KDIGObin criterion; (b) SCr and UrNGAL levels stratified by type of AmB preparation. SCr, serum creatinine; UrNGAL, urine neutrophil gelatinase-associated lipocalin; AKI, acute kidney injury; AmB, amphotericin B; Deoxy, AmB deoxycholate; Lipo, liposomal AmB; KDIGObin criterion, the Kidney Disease: Improving Global Outcomes criterion that requires an increase in the SCr level by ≥0.3 mg/dl within 48 h or an increase in the SCr to ≥1.5 times the baseline level which is known or presumed to have occurred within the prior 7 days. Squares and circles, means; bars, standard errors of the means. SCr levels (black) are plotted on the primary y axis (left), and UrNGAL levels (gray) are plotted on the secondary y axis (right).